Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > L2, CLAS have lot of potential buyers

<< Previous

Bullboard Posts

Next >>

Comment by whisky11on May 13, 2022 12:14pm

113 Views

Post# 34681892

RE:RE:RE:RE:L2, CLAS have lot of potential buyers

whisky11;I'm not pis, I,ve invested for the product. R-107is great, I love the science behind it and opportunity to make fortune with a small investment.
I think phase 1 started. That would be a reason why they diverted money from Financial Report to phase 1.
They didn't have money to proceed with two of them, so they choose to delay less important/damaging one to the company as whole.

Red~One]Hey I'd be pis sed too, if I were you..... don't shoot the messenger and if you're looking for trolls you missed the mark. BTW is CLAS in Phase 1 Trials ?

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec